[go: up one dir, main page]

UA80991C2 - Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes - Google Patents

Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes Download PDF

Info

Publication number
UA80991C2
UA80991C2 UAA200504320A UA2005004320A UA80991C2 UA 80991 C2 UA80991 C2 UA 80991C2 UA A200504320 A UAA200504320 A UA A200504320A UA 2005004320 A UA2005004320 A UA 2005004320A UA 80991 C2 UA80991 C2 UA 80991C2
Authority
UA
Ukraine
Prior art keywords
solid preparation
active ingredient
average size
insulin
insulin sensitizer
Prior art date
Application number
UAA200504320A
Other languages
English (en)
Ukrainian (uk)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32064024&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA80991(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of UA80991C2 publication Critical patent/UA80991C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
UAA200504320A 2002-10-07 2003-06-10 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes UA80991C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002294045 2002-10-07
PCT/JP2003/012781 WO2004030700A1 (ja) 2002-10-07 2003-10-06 固形製剤

Publications (1)

Publication Number Publication Date
UA80991C2 true UA80991C2 (en) 2007-11-26

Family

ID=32064024

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200504320A UA80991C2 (en) 2002-10-07 2003-06-10 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes

Country Status (25)

Country Link
US (1) US9101660B2 (ja)
EP (1) EP1561472B2 (ja)
JP (2) JP4236553B2 (ja)
KR (2) KR20070119095A (ja)
CN (1) CN100427143C (ja)
AU (1) AU2003271103B2 (ja)
BR (1) BR0315082A (ja)
CA (1) CA2501587C (ja)
CO (1) CO5700740A2 (ja)
CR (1) CR7797A (ja)
CY (1) CY1114863T1 (ja)
DK (1) DK1561472T3 (ja)
ES (1) ES2437072T5 (ja)
IL (1) IL167835A (ja)
MA (1) MA27487A1 (ja)
MX (1) MXPA05003668A (ja)
NO (1) NO332993B1 (ja)
NZ (2) NZ552559A (ja)
PL (1) PL219608B1 (ja)
PT (1) PT1561472E (ja)
RU (1) RU2357757C2 (ja)
SI (1) SI1561472T1 (ja)
UA (1) UA80991C2 (ja)
WO (1) WO2004030700A1 (ja)
ZA (1) ZA200503507B (ja)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7976853B2 (en) 2003-01-29 2011-07-12 Takeda Pharmaceutical Company Limited Process for producing coated preparation
US7198653B2 (en) 2003-07-31 2007-04-03 Delavau Llc Calcium carbonate granulation
PT1677792E (pt) 2003-10-31 2016-02-09 Takeda Pharmaceutical Preparação sólida compreendendo pioglitazona, glimepirida e um éster de ácido gordo de polioxietileno sorbitano
CA2562391A1 (en) 2004-04-14 2005-10-27 Takeda Pharmaceutical Company Limited Solid pharmaceutical preparation
EP2204169A1 (en) * 2005-04-26 2010-07-07 Dainippon Sumitomo Pharma Co., Ltd. Granular preparation containing biguanide compound
RU2426530C2 (ru) 2005-12-22 2011-08-20 Такеда Фармасьютикал Компани Лимитед Твердый препарат
KR101220643B1 (ko) * 2006-08-16 2013-01-14 알리코제약(주) 사포그릴레이트 함유 경구투여 형태의 약제
US9138414B1 (en) 2006-09-15 2015-09-22 Delavau Llc Calcium supplement having enhanced absorption
JP4832271B2 (ja) * 2006-12-11 2011-12-07 花王株式会社 粉末圧縮錠剤
KR101536786B1 (ko) 2007-07-19 2015-07-14 다케다 야쿠힌 고교 가부시키가이샤 알로그립틴 및 메트포르민 히드로클로라이드를 포함하는 고체 제제
US8563500B2 (en) 2007-09-05 2013-10-22 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Methods and compounds for treating diseases caused by reactive oxygen species
CN101417130B (zh) * 2007-10-22 2010-10-06 鲁南制药集团股份有限公司 一种治疗ⅱ型糖尿病及其并发症的药物组合物
TR200803177A2 (tr) * 2008-05-06 2009-11-23 Bi̇li̇m İlaç Sanayi̇ Ti̇caret A.Ş. Antihiperglisemik etkili metformîn - pioglitazon formülasyonu.
WO2010084504A2 (en) * 2008-05-26 2010-07-29 Sun Pharmaceutical Industries Ltd. A stable, oral solid dosage form
US20110009347A1 (en) * 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
TW201138843A (en) 2009-12-18 2011-11-16 Colgate Palmolive Co Biguanide preservation of precipitated calcium carbonate
EP2633857B1 (en) 2009-12-23 2015-08-12 ratiopharm GmbH Solid pharmaceutical dosage form of ticagrelor and acetylsalicylic acid
WO2012012156A1 (en) * 2010-07-21 2012-01-26 Myomics, Inc. Methods and compositions for the improvement of skeletal muscle function in a mammal
EP2441442A1 (en) 2010-10-08 2012-04-18 LEK Pharmaceuticals d.d. A pharmaceutical composition comprising a thiazolidinedione
TWI631963B (zh) * 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
RU2465896C2 (ru) * 2011-01-20 2012-11-10 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая противодиабетическая композиция пролонгированного действия
CN105125539A (zh) * 2015-08-05 2015-12-09 浙江华海药业股份有限公司 吡格列酮二甲双胍片及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0553777B1 (en) 1992-01-29 2002-04-24 Takeda Chemical Industries, Ltd. Fast dissolving tablet and its production
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
ATE400299T1 (de) * 1996-07-12 2008-07-15 Daiichi Seiyaku Co Schnell zerfallende, druckgeformte materialien sowie prozess zu deren herstellung
US6153632A (en) 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
US6291495B1 (en) 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US20020004515A1 (en) 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
AP1279A (en) 1997-06-18 2004-05-20 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and metformin.
GB9715295D0 (en) 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
JPH1160476A (ja) 1997-08-25 1999-03-02 Taisho Pharmaceut Co Ltd 圧縮固形組成物
EP1063973B1 (en) 1998-03-19 2016-11-16 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
TW585786B (en) * 1998-07-28 2004-05-01 Takeda Chemical Industries Ltd Lansoprazole-containing rapidly disintegrable solid pharmaceutical composition
US6117451A (en) * 1998-08-25 2000-09-12 Pharmalogix, Inc. Direct compression metformin hydrochloride tablets
EA200601145A1 (ru) * 1998-11-12 2009-04-28 Смитклайн Бичам П.Л.С. Таблетка замедленного высвобождения сенсибилизатора к инсулину и других антидиабетических агентов
DK1143955T3 (da) 1998-12-24 2005-11-14 Metabasis Therapeutics Inc En kombination af FBPase-inhibitorer og insulinsensibiliseringsmidler til behandling af diabetes
CA2371391A1 (en) 1999-04-29 2000-11-09 City Of Hope Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (age's)
AR028299A1 (es) 1999-09-17 2003-05-07 Novartis Ag Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
AU1403501A (en) 1999-11-16 2001-05-30 Smithkline Beecham Plc Novel composition and use
MY125516A (en) * 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
US6403121B1 (en) 2000-05-01 2002-06-11 Aeropharm Technology Incorporated Core formulation
US6780432B1 (en) 2000-05-01 2004-08-24 Aeropharm Technology, Inc. Core formulation
US6524621B2 (en) 2000-05-01 2003-02-25 Aeropharm Technology Inc. Core formulation
JP2001335469A (ja) * 2000-05-26 2001-12-04 Lion Corp 固体製剤の製造方法
FR2812547B1 (fr) 2000-08-04 2002-10-31 Lipha Composition pharmaceutique comprenant une association metformine et derive de thiazolidinedione et son utilisation pour la preparation de medicaments destines a traiter le diabete
JP2002087965A (ja) 2000-09-14 2002-03-27 Lion Corp 口中崩壊性アスピリン含有錠剤
US7510728B2 (en) 2000-10-06 2009-03-31 Takeda Pharmaceutical Company Limited Solid preparations
JP4284017B2 (ja) * 2000-10-06 2009-06-24 武田薬品工業株式会社 固形製剤
UA80393C2 (uk) 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
CA2492722A1 (en) 2002-07-11 2004-01-22 Takeda Pharmaceutical Company Limited Production method of coated preparations

Also Published As

Publication number Publication date
RU2005113999A (ru) 2005-12-10
DK1561472T3 (da) 2013-11-11
WO2004030700A1 (ja) 2004-04-15
MXPA05003668A (es) 2005-06-08
EP1561472B2 (en) 2021-01-20
MA27487A1 (fr) 2005-08-01
CN1717253A (zh) 2006-01-04
EP1561472A4 (en) 2009-07-08
HK1080385A1 (en) 2006-04-28
CA2501587C (en) 2008-06-03
ES2437072T3 (es) 2014-01-08
KR20070119095A (ko) 2007-12-18
US9101660B2 (en) 2015-08-11
CN100427143C (zh) 2008-10-22
ZA200503507B (en) 2006-08-30
NZ539711A (en) 2007-09-28
US20050287207A1 (en) 2005-12-29
IL167835A (en) 2010-11-30
JP4236553B2 (ja) 2009-03-11
RU2357757C2 (ru) 2009-06-10
JP2008208141A (ja) 2008-09-11
BR0315082A (pt) 2005-08-16
PL219608B1 (pl) 2015-06-30
KR20050070039A (ko) 2005-07-05
CA2501587A1 (en) 2004-04-15
NO332993B1 (no) 2013-02-11
SI1561472T1 (sl) 2014-01-31
NO20052239L (no) 2005-06-29
PL376176A1 (en) 2005-12-27
EP1561472B1 (en) 2013-10-02
AU2003271103B2 (en) 2008-02-28
KR100820609B1 (ko) 2008-04-10
CR7797A (es) 2005-11-15
CY1114863T1 (el) 2016-12-14
PT1561472E (pt) 2013-12-09
NZ552559A (en) 2008-04-30
CO5700740A2 (es) 2006-11-30
NO20052239D0 (no) 2005-05-06
AU2003271103A1 (en) 2004-04-23
ES2437072T5 (es) 2021-10-13
EP1561472A1 (en) 2005-08-10
JP2004149521A (ja) 2004-05-27

Similar Documents

Publication Publication Date Title
UA80991C2 (en) Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
KR101114808B1 (ko) 피복 제제의 제조법
JP5276991B2 (ja) 固形製剤
JP5162475B2 (ja) ピオグリタゾンを含有する経口剤
RU2359671C2 (ru) Способ получения препарата с покрытием
CA3101822A1 (en) Pharmaceutical combination, composition, and combination formulation containing glucokinase activator and ppar receptor activator, and preparation methods and uses thereof
JP5179363B2 (ja) 固形製剤
KR100952090B1 (ko) 인슐린 감작제, 인슐린 분비촉진제 및 폴리옥시에틸렌소르비탄 지방산 에스테르를 함유하는 고체 제제
JP4739189B2 (ja) 固形製剤
JP4567340B2 (ja) 被覆製剤の製造方法
JP4361461B2 (ja) 固形製剤
JP4478413B2 (ja) 被覆製剤の製造法
JP2005015477A (ja) 固形製剤
HK1080385B (en) Solid preparation
KR20050017090A (ko) 코팅제의 제조 방법
HK1084038A (en) Process for producing coated preparation
TW201219384A (en) Pharmaceutical composition for the treatment of type 2 diabetes in mammals including human beings